Adalimumab Drug Levels Predict Efficacy Save

In a prospective study of 311 rheumatoid arthritis patients starting either adalimumab (ADA) or etanercept, investigators sought to correlate drug levels and/or anti-drug antibodies with clinical outcomes (citation source http://url.ie/z237). ADA levels best predicted DAS28 at 12 months (R= 0.060) and low drug levels were associated with BMI > 30 and nonadherence. Anti-ADA drug antibody formation and low ADA levels were best at predicting the EULAR response at 12 months (see video).
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.